Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23867147 | 1.00 | HSP90AB1 (0.44) | HSP90AB1GABRA1GABRB2MAOBKDM4E | |
| SCHEMBL11044980 | 1.00 | HSP90AB1 (0.44) | HSP90AB1GABRA1GABRB2MAOBKDM4E | |
| SCHEMBL11044983 | 1.00 | HSP90AB1 (0.44) | HSP90AB1GABRA1GABRB2MAOBKDM4E | |
| SCHEMBL11044986 | 1.00 | HSP90AB1 (0.44) | HSP90AB1GABRA1GABRB2MAOBKDM4E | |
| SCHEMBL11045985 | 1.00 | HSP90AB1 (0.44) | HSP90AB1GABRA1GABRB2MAOBKDM4E | |
| SCHEMBL18655389 | 0.80 | DYRK1A (0.57) | HSP90AB1GABRA1GABRB2KDM4EHSD17B10 | |
| SCHEMBL4363910 | 0.80 | AR (0.50) | MAOBHSD17B10ARCYP19A1SLC8A1 | |
| SCHEMBL16376659 | 0.79 | CYP2C19 (0.47) | HSP90AB1GABRA1GABRB2MAOBKDM4E | |
| SCHEMBL8504530 | 0.79 | CHRM2 (0.41) | GABRA1GABRB2MAOBCHRM2CHRM4 | |
| SCHEMBL1659934 | 0.78 | CYP3A4 (0.48) | HSP90AB1GABRA1GABRB2MAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0025599-A1 | Benzopyran compounds, useful as chemotherapeutic agents | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-25 | — | — | EP | claimed |
| US-7820835-B2 | Method for producing flavan derivatives | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20090099374-A1 | METHOD FOR PRODUCING FLAVAN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2009-04-16 | — | — | US | disclosed |
| EP-0025599-B1 | BENZOPYRAN COMPOUNDS, USEFUL AS CHEMOTHERAPEUTIC AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-12-19 | — | — | EP | disclosed |
| US-4452991-A | OR BENZO(B)INDENO (2,1-E) PYRANS OR BENZO(C)XANTHENES | BATCHELOR JOHN F (GB) | 1984-06-05 | — | — | US | disclosed |
| EP-0025599-A1 | Benzopyran compounds, useful as chemotherapeutic agents | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099374-A1 | METHOD FOR PRODUCING FLAVAN DERIVATIVE | ADH5, ADH1C, CYP2E1 | HSP90AB1 2562/4885GABRA1 4193/4885GABRB2 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.